No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.9x · 10Y median 2.5x · 64th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:32:38.656Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for LifeStance Health Group, Inc. (LFST) stock was $11.95 as of Oct 6, 2026, 10:30 AM EDT, down 2.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +120.9% · 3-year avg +24.6%/yr · 5-year avg -1.5%/yr
LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network.
Medical - Care Facilities · Scottsdale, AZ
LATEST PRICE
$11.95
52-WEEK RANGE
$4.77 - $13.56
BETA
1.22
% FROM 52W HIGH
-11.87%
MARKET CAP
$4.63B
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
92.14
PE RATIO (FWD)
forward FY estimate
74.44
P/B RATIO
3.14
P/S RATIO
TTM
2.92
P/OCF RATIO
TTM
21.27
EV/EBITDA
TTM
34.66
DEBT / EQUITY
0.14
REVENUE TTM
$1.58B
GROSS MARGIN TTM
33.56%
NET PROFIT MARGIN TTM
3.19%
REVENUE GROWTH TTM
TTM vs prior TTM
+20.38%
REVENUE CAGR 3Y
+18.22%
REVENUE CAGR 5Y
+24.79%
TTM TOTAL RETURN
+120.94%
3Y TOTAL RETURN
annualized (CAGR)
+24.64%
5Y TOTAL RETURN
annualized (CAGR)
-1.46%
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
0.04
Revenue Est.
$431.60M
Last Quarter Results
EPS
$0.11
vs Estimate
$0.08
Revenue
$435.35M
vs Estimate
$414.58M
Consensus Rating
Based on 10 analysts
Average Price Target
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.02 | $0.04 | $0.05 | 4 |
| Quarter ending Dec 2026 | $0.03 | $0.04 | $0.05 | 4 |
| Quarter ending Mar 2027 | $0.07 | $0.07 | $0.07 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LFST | $4.63B | $11.95 | -2.21% | +120.94% | -1.46% | N/A | N/A |
| 2DFTX | $4.64B | $34.97 | -3.48% | +187.00% | +1.43% | N/A | vs LFST |
| 3DNTH | $4.73B | $84.55 | -3.97% | +150.87% | -5.50% | N/A | vs LFST |
| 4BLLN | $4.74B | $103.00 | -5.56% | N/A | N/A | N/A | vs LFST |
| 5ADPT | $4.47B | $27.91 | -6.47% | +106.79% | -1.77% | N/A | vs LFST |
| 6MIRM | $4.82B | $79.10 | -2.86% | +11.57% | +37.24% | N/A | vs LFST |
$14.40
+20.5% upside
Low
$12.00
Current
$11.95
High
$18.00
| 1 |
| Quarter ending Jun 2027 | $0.08 | $0.08 | $0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.14 | $0.16 | $0.17 | 5 |
| FY 2027 | $0.21 | $0.22 | $0.23 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $431.08M | $431.60M | $431.91M | 6 |
| Quarter ending Dec 2026 | $437.58M | $438.56M | $439.46M | 6 |
| Quarter ending Mar 2027 | $457.45M | $460.76M | $465.40M | 3 |
| Quarter ending Jun 2027 | $488.99M | $492.52M | $497.48M | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.69B | $1.71B | $1.72B | 7 |
| FY 2027 | $1.94B | $1.96B | $1.98B | 7 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
